JustPharmaReports.com

Over the past 20 years, JustPharma's analyst has written more than 50 major reports and numerous articles for many leading trade publishers. Those on global pricing and reimbursement (including the first ever journal dedicated to P&R, Pharma Pricing Review), European integration, parallel trade, wholesale and retail distribution, hospital drug procurement, orphan drugs, generics and Japan have become industry standards. These topics will be further developed and others added by the author, but only from now under the justpharmareports label. If you are tired and confused with over-complicated Powerpoint presentations that tend to lose all meaning over time, you will welcome the clear, succinct and eminently readable style of justpharmareports, where the emphasis is on imparting understanding.
Every report deals with the subject comprehensively in a neutral, fact-based manner. Each is based on up-to-the-minute research by the author - largely primary research in the field - among leading experts on the topic concerned. All have a logical layout and are clearly indexed. As well as major reports you will find occasional short briefing notes and articles on topical subjects.

JustPharmaReports.com
 

List of reports from JustPharmaReports.com

Market Access Taiwan
11/1/2012 | published by: JustPharmaReports.com
... be modified and the importance of health technology assessment (HTA) reaffirmed. The Cross-Strait Co-operation Agreement on Medicine and Public Health Affairs with mainland China might be of even greater significance in the longer term as ...  |  more...
$1,420.00
Biosimilars: Current Situation & Future Prospects, Worldwide
3/1/2012 | published by: JustPharmaReports.com
... biologics market expected to lose some degree of protection by 2019. All major countries now make provision for an abbreviated biosimilar development and regulatory pathway. Funds are flowing into the sector and many new partnership ...  |  more...
$3,000.00
Pharmaceutical Pricing & Distribution in Japan, 2010 Update
10/1/2011 | published by: JustPharmaReports.com
... optimise market access and life cycle management into 60 pages and offers tremendous value. Completely updated, it explains all the latest changes to the NHI pricing rules, including the important new price premium for developing ...  |  more...
$760.00
Orphan Drugs in Europe: Pricing, Reimbursement, Funding & Market Access Issues, 2011 Edition
6/1/2011 | published by: JustPharmaReports.com
... strong patient voice and the treatments themselves sometimes offer the only hope. But is this enough to assure premium prices and special status in an era of budget limitations, and growing demands for evidence of ...  |  more...
$2,300.00
Market Access Korea: Breaking into the Developed World's Fastest Growing Pharmaceutical Market
11/1/2010 | published by: JustPharmaReports.com
... have seen total sales growth of 15.6%, 13.5%, 12.4% and 13.8% respectively. IMS forecasts CAGR of 6.5% from 2010 through 2015, making Korea the fastest growing developed market for medicines in the world. Currently ranked ...  |  more...
$1,380.00
Orphan Drugs in Asia-Pacific: From Designation to Pricing, Funding & Market Access
2/1/2010 | published by: JustPharmaReports.com
... measures to promote the development, registration and/or commercialisation of rare disease treatments. Singapore’s Medicines (Orphan Drug) Exemption Order of 1991 was the first legislation anywhere to follow the US Orphan Drug Act, with the other ...  |  more...
$2,320.00
Distribution and Patient Support for Speciality Medicines in Europe
9/1/2009 | published by: JustPharmaReports.com
... and handling, with help with dosage administration, close monitoring and ongoing support for the patient needed. Manufacturers of speciality medicines seek a competitive advantage through distribution optimisation, including responsive, efficient and cost effective logistics, better ...  |  more...
$1,050.00
Prospects for Legalizing Drug (Re-)Importation to the United States
6/1/2009 | published by: JustPharmaReports.com
... on this promise with a fiscal 2010 budget request for funds ‘to allow the FDA to begin developing policies for drug importation’. Earlier in 2009, with strong bipartisan support, Senator Bryon Dorgan (D-ND) re-tabled a ...  |  more...
$1,600.00
Complete Guide to the 2009 PPRS, NICE & other Pharmaceutical Cost Containment Measures in the United Kingdom
4/1/2009 | published by: JustPharmaReports.com
... Health and Clinical Excellence in April. PPRS and NICE, are among abbreviations most widely recognised, but their structures, functions and ways of working are often less than fully understood. ‘Complete Guide to the 2009 PPRS, ...  |  more...
$1,350.00
Pharmacy Liberalisation in Europe: Prospects and Implications
9/1/2008 | published by: JustPharmaReports.com
... the arguments put to it forcefully by the European Commission and by DocMorris, revolutionary reform among industry’s main customer group, the community pharmacist, in several of the main countries, including 4 of the EU-5, will ...  |  more...
$905.00
Access to Hospital Pharmaceutical Markets in the United Kingdom
8/1/2008 | published by: JustPharmaReports.com
... products also unable to get established for maintenance therapy in the community without hospital recommendation first. Though the processes for achieving hospital usage are very different to the reimbursed GP/community pharmacy sector, they have been ...  |  more...
$1,350.00
Pharmaceutical Pricing and Distribution in Japan: The Keys to Success in the World’s Second Largest Market
6/1/2008 | published by: JustPharmaReports.com
... can be introduced without a yakka (reimbursement price) set by the government. Innovative new drugs receive price premiums while others are capped at the price of older entrants. Discounting to the trade is inescapable, but ...  |  more...
$2,700.00
 

Research assistance

We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 

Join Alert Me now!

Receive bi-weekly email alerts on new market research

Sign up today!